Even though Meso-TR3 demonstrated several favorable properties, such as improved bioactivity on MUC16-expressing tumors in vitro and in vivo, we suspected that it's relatively large molecular weight could prove prohibitive when it comes to drug penetration into solid tumors, as these are often characterized by extensive stromal components, especially relevant in pancreatic cancer [29, 30]. The gene discussed is MUC16; the disease is familial pancreatic carcinoma.